| Related Articles |
Pharmaceutical Approval Update.
P T. 2018 Dec;43(12):734-735
Authors: Kaufman MB
Abstract
Mulpleta (lusutrombopag) for thrombocytopenia; ajovy (fremenezumab-vfrm) for migraine; takhzyro (lanadelumab-flyo) for hereditary angioedema attacks.
PMID: 30559583 [PubMed]